🇺🇸 FDA
Patent

US 9206245

Immunogenic peptides and methods of use for treating and preventing cancer

granted A61KA61K39/0011A61K40/11

Quick answer

US patent 9206245 (Immunogenic peptides and methods of use for treating and preventing cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K39/0011, A61K40/11, A61K40/42, A61P